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mortality was not signiﬁcant during either follow-up window (30-day
p ¼ 0.249; 1-year p ¼ 0.253; see Figure), but showed a trend to higher
mortality in patients with very low BSA.
CONCLUSIONS No signiﬁcant association between BSA and mortality
after TAVR was detected. While there was a trend towards increased
mortality in patients with lower BSA, larger studies are needed to
provide deﬁnitive answers. As with BMI, BSA might be of prognostic
value for patients undergoing TAVR.
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BACKGROUND Valve types for transcatheter aortic valve implanta-
tion (TAVI) have undergone rapid evolution. The new balloon-
expandable Edwards Sapien-3 (S3) valve offers several novel features
to prevent or reduce typical TAVI-related problems such as para-
valvular leaks (PVLs) and vascular complications. The aim of this
study was to investigate the potential differences in the clinical
outcome compared to its predecessor Sapien XT (SXT).
METHODS We analyzed n¼400 consecutive patients undergoing TAVI
at our institution from 2012-2015 using balloon-expandable Edwards
Sapien-3 (n¼200, 61% transfemoral (TF), 27.5% transaortic (TAo), 11.5%
transapical (TA)) and Sapien XT (n¼200, 52.5% TF, 27.5% TAo and
20.0% TA) prostheses. The change in valve type was in 02/2014. All
patients were available for complete retrospective analyses. The
severity of paravalvular AR was evaluated with echocardiography 7d
after TAVI. The outcomewas analyzed according to the VARC-2 criteria.
RESULTS Comparison of both baseline characteristics of both groups
showedahigher surgical risk score for theSapien-3 group (meanSTS score S3
8.6% % (7.1) vs SXT 6.4% % (4.1)) and a higher rate of previous cardiac
surgery in SXT group (S3 30.0% vs. SXT 48.5%, p<0.001). No differences
between groups could be detected in mean age, sex, previous pacemaker
implantations, LV function, cardiovascular risk factors, COPD, and pAVK.
Despite higher surgical risk of the S3patientswe couldnot detect a difference
in 30dmortality betweenboth groups (S3 7.5%vs. SXT7.0%). Postprocedural
echocardiographyrevealed lessmildandmoderatePVLs inS3 (0%moderate,
18.8%mild AR) patients than SXT patients (4.6%moderate and 40.8%mild,
p<0.001). In addition, postdilatationwas carried outmore frequently in SXT
patients (46.0% pts vs. 23.0% pts, p<0.001). However, the use of the S3
prosthesiswasassociatedwith increased risk fornewconductiondisturbance
requiring new pacemaker implantation (S3 10.8% vs. SXT 5.2%, p¼0.05).
CONCLUSIONS Theseﬁndings indicate that theuseof theEdwardsSapien-
3device leads to reducednumbersof signiﬁcantPVLs.Yetwecoulddetect an
increased need for new pacemaker implantation in S3 patients. Future in-
vestigations aim to analyze the potential effects on long-term survival.
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BACKGROUND Direct transcatheter aortic valve implantation (TAVI)
has shown to be safe and feasible with a similar success rate to TAVI
with prior balloon aortic valvuloplasty (BAV). The aim of this study
was to evaluate the effect of direct TAVI on long-term mortality with a
self-expanding bioprosthesis.
METHODS Prospectively collected data before and after TAVI from
two high-volume centers were retrospectively analyzed in all pa-
tients. Primary clinical end-point was all-cause mortality at 1 year. All
outcomes were evaluated according to the VARC-2 criteria.
RESULTS We included 210 patients in the study (120 patients for non-
direct TAVI and 90patients for direct TAVI). Both groups had similar 1-year
mortality rates (15% in non-direct versus 11% in direct, p¼0.5). No major
differenceswereobserved concerning cardiovascular death (3%versus 2%,
p¼0.9), stroke (3% versus 5%, p¼0.4) and acute myocardial infarction (2%
versus0%, p¼0.2), in non-direct anddirect TAVI groups respectively in the
mid-term. The direct grouphad lessmoderate/severe paravalvular leakage
(PVL) post TAVI compared to the non-direct group (8% vs 27%, p<0.01). At
univariate analysis, predictors formortalitywere: BAVbefore TAVI (p¼0.2,
OR: 1.71, 95%CI: 0.742-3.939), logEuroscore (p<0.044, OR: 1.046, 95%CI:
1.001-1.093), failure to achieve device success (p¼0.143, OR: 1.795, 95%CI:
0.821-3.926) and the interventricular septum thickness (p<0.048, OR:
1.249, 95%CI: 1.002-1.555). Atmultivariate analysis, independent predictor
of mortality was logEuroscore (p<0.035, OR: 1.058, 95%CI: 1.004-1.114).
CONCLUSIONS Direct TAVI is safe and comparable outcomes are
achieved with the current practice of TAVI with balloon aortic val-
vuloplasty. Further studies are necessary to assess the long-term
mortality and effect on PVL of direct TAVI.
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BACKGROUND Transcutaneous aortic valve implantation (TAVI)
signiﬁcantly improves the prognosis of inoperable patients with severe
aortic stenosis and appears to be equivalent to surgery in high-risk
patients. However, limitations of ﬁrst-generation devices regarding
repositioning and optimization of placement can result in complica-
tions and hence increase mortality. Therefore, it was the aim of this
study to evaluate the performance of a resheathable and repositionable
self-expanding TAVI system in high risk patients with aortic stenosis.
METHODS This prospective, single arm, multicentre study evaluated
the safety and efﬁcacy of the PorticoTM Transcatheter Aortic Valve
Implantation System. Between March 2012 and April 2014 102 patients
(97% Female; Mean Age: 845 years; STS Score: 6.23.5, logistic
EuroScore: 16.77.5 %) were treated at 7 sites in the UK, and Germany
using the 18F Portico Delivery System with a 23 or 25mm Portico
Valve. Patients were followed post procedure at 30, 90, 180 days and
1 year. Adverse events were categorized by VARC deﬁnitions and
adjudicated by an independent events committee. Echocardiography
was evaluated by an independent laboratory.
